FAQs & How to use this site
Home | About Us | Contact Us
The Front Line

 

The Front Line: Charles D. Blanke, MD, SWOG Chair
ABOUT

PREVIOUS POSTS November 2017

October 2017 September 2017 August 2017 July 2017 June 2017 May 2017 April 2017 March 2017 February 2017 January 2017 December 2016 November 2016 October 2016 September 2016 August 2016 July 2016 JUNE 2016 MAY 2016 APRIL 2016 MARCH 2016 FEB 2016 JAN 2016 DEC 2015 NOV 2015 OCT 2015 SEP 2015 AUG 2015 JUL 2015 JUN 2015 MAY 2015 APR 2015 MAR 2015 FEB 2015 JAN 2015 DEC 2014 NOV 2014 OCT 2014 SEP 2014 AUG 2014 JUL 2014 JUN 2014 MAY 2014 APR 2014 MAR 2014 FEB 2014 JAN 2014 DEC 2013 NOV 2013 OCT 2013 SEP 2013 AUG 2013 JUL 2013

Are We Really Making An Impact?

December 23, 2016 - Here at the bottom of 2016, I’m thinking a lot about impact. I refuse to use the word “impactful,” but I want our work to actually make a difference, as you do, for oncology research and the public we serve.

We’ve had a raft of impressive SWOG research results recently, and we sent out press releases out this week on two important findings. They’re classic SWOG – a negative finding by Dr. Peter Lance blows another hole in the idea that antioxidant supplements prevent cancer. The other is a positive result in The Lancet by Dr. Brian Durie, illustrates the promise of a new triple drug combination for myeloma. What a great way to end the year!

For SWOG, 2016 was a big year. We celebrated our 60th anniversary together, and reviewed our work formally. Since 1956, our research has led to FDA approval of 14 new drugs. We’ve changed the standard of care in cancer over 100 times. And, thanks to innovative biostatistical work by our own Dr. Joe Unger, I was able to announce from the plenary podium in Chicago that our research studies have saved more than 2 million years of human life. From that same stage, Craig Blanford, a bladder cancer survivor from Texas treated on our own BCG immunotherapy protocol, called you all heroes. Which you are.

All the progress SWOG has made comes thanks to our patients and to you. Members drive our organization. You come up with compelling trial ideas, and develop strong protocols that make testing them possible. You help SWOG better manage our trials, better improve accrual, and better connect with each other. SWOG members bring the best science into our work, and bring in the best new minds in cancer research into the group.

What kind of end-of-the year column doesn’t fundraise a little bit? Not this one! Earlier this year, The Hope Foundation launched a matching campaign. If we gave $100,000, we’d get through a generous match a total of $200,000 to support research, training, and travel for SWOG young investigators. Hope is only about $20,000 shy of their goal. A series of small donations or just a few well-heeled members giving more generous gifts will help us get there.

In 2017, I’ll continue to focus on impact. I’ll be working with my leadership team on a dashboard that will show key data points – such as accrual and time to trial – that we can use to improve our work. When this column resumes January 6, it will include SWOG’s first annual impact report, with statistics and highlights from 2016.

So, do we make an impact? I think you know my answer. Thank you for your service to SWOG, and happiest holiday season to you. See you in the new year.

 
     
SWOG Logo Disclaimer | Copyright ©1999-2017 SWOG. All rights reserved.
Design and Hosting by nuMedia
SWOG is FISMA CertifiedSWOG is FISMA Certified